<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00332969</url>
  </required_header>
  <id_info>
    <org_study_id>CSMS995ADE13</org_study_id>
    <nct_id>NCT00332969</nct_id>
  </id_info>
  <brief_title>Efficacy of Octreotide Treatment in Patients With Primary Inoperable Thymoma</brief_title>
  <official_title>Efficacy of Medical Treatment With Octreotide in Patients With Primary Inoperable Thymoma to Reduce Tumor Size</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study will investigate the efficacy of treatment with octroetide in patients with
      primary inoperable thymoma to reduce tumor size.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Shrinkage of tumor size and diameter of 3 respectively 6 months</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Resection status after 3 respectively 6 months</measure>
    <time_frame>3 - 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Thymoma</condition>
  <arm_group>
    <arm_group_label>Sandostatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Octreotide</intervention_name>
    <arm_group_label>Sandostatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female patients aged &gt;18 years

          2. Inoperability of thymic tumor. Inoperability is defined as at least adherence of the
             tumor to the neighbour organs, suspicious to infiltrate neighbour organs so that R0
             resection cannot be expected.

          3. Positive result in SMS-szintigraphy,

          4. Thymomas of all WHO based histological subtypes (Rosai, 1999; Travis 2004) at Masaoka
             stage III based on histological examination of core biopsies or resection specimens.

          5. Patients with and without thymoma associated paraneoplastic syndrome

          6. Demonstrated tolerance to a test dose of s.c. octreotide injection at Visit 1.

        Exclusion Criteria:

          1. Performance status 0,1, or 2 (ECOG)

          2. Symptomatic cholelithiasis,

          3. Pretreatment with octreotide (longn acting release) within the 3 months

          4. Patient has received any other investigational agents within 28 days of first day of
             study drug dosing

          5. Patient is &lt; 5 years free of another primary malignancy except: if the other primary
             malignancy is not currently clinically significant nor requiring active intervention,
             or if other primary malignancy is a basal cell skin cancer or a cervical carcinoma in
             situ. Existence of any other malignant disease is not allowed

          6. Grade III/IV cardiac problems as defined by the New York Heart Association Criteria.
             (i.e., congestive heart failure, myocardial infarction within 6 months of study)

        Other protocol-defined inclusion/exclusion criteria apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmeceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Regensburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=5264</url>
    <description>Results for CSMS995ADE13 on the Novartis Clinical Trials Website</description>
  </link>
  <results_reference>
    <citation>Kirzinger L, Boy S, Marienhagen J, Schuierer G, Neu R, Ried M, Hofmann HS, Wiebe K, Str√∂bel P, May C, Kleylein-Sohn J, Baierlein C, Bogdahn U, Marx A, Schalke B. Octreotide LAR and Prednisone as Neoadjuvant Treatment in Patients with Primary or Locally Recurrent Unresectable Thymic Tumors: A Phase II Study. PLoS One. 2016 Dec 16;11(12):e0168215. doi: 10.1371/journal.pone.0168215. eCollection 2016.</citation>
    <PMID>27992479</PMID>
  </results_reference>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 1, 2006</study_first_submitted>
  <study_first_submitted_qc>June 1, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2006</study_first_posted>
  <last_update_submitted>March 30, 2017</last_update_submitted>
  <last_update_submitted_qc>March 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Open label</keyword>
  <keyword>phase II</keyword>
  <keyword>disease</keyword>
  <keyword>clinical trial</keyword>
  <keyword>Octreotide</keyword>
  <keyword>thymoma</keyword>
  <keyword>cancer</keyword>
  <keyword>tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thymoma</mesh_term>
    <mesh_term>Thymus Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Octreotide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

